DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

Study shows the DecisionDx-Melanoma test identifies more patients who can safely forego SLNB than using current guidelines alone or a clinicopathologic-only nomogram

...

Related Keywords

New Jersey ,United States ,American ,Castle Biosciences ,Castle Decisiondx ,Michael Tassavor ,Instagram ,Facebook ,Memorial Sloan Kettering Cancer Center ,Nasdaq ,Castle Biosciences Inc ,Anticancer Research ,Linkedin ,Securities Exchange ,American Joint Committee On Cancer ,National Comprehensive Cancer Network ,American Joint Committee ,Mypath Melanoma ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Report ,Markets ,